Korro Bio, Inc. (KRRO)Healthcare | Biotechnology | Cambridge, United States | NasdaqCM
8.81 USD
-0.56
(-5.977%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 9:19 a.m. EDT
The fundamental reality here is stark: Korro Bio is a speculative biotech venture with no earnings, negative free cash flow, and a balance sheet that requires constant capital raising. While the company recently posted a price recovery, the underlying business metrics—negative operating margins and a lack of profitability—are severe red flags for any rational investor. The recent surge in stock price appears to be driven by analyst upgrades and potential clinical trial optimism, but the market is clearly pricing in a high probability of failure, evidenced by the heavy put writing at deep strikes. The statistical forecast suggests a slight upward lean, but given the 'LOW' confidence rating and the company's precarious financial position, this is likely noise rather than a reliable trend. For a short-term trader, the volatility offers a chance to profit from a bounce, but the risk of a sharp correction remains high. Long-term investors should avoid this security entirely; the business model is not yet proven, and the capital structure is fragile. There is no margin of safety here, only a lottery ticket with a high probability of expiring worthless. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.110829 |
| AutoTheta | 0.165191 |
| AutoETS | 0.165287 |
| MSTL | 0.174183 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 40% |
| H-stat | 3.36 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.052 |
| Excess Kurtosis | -0.69 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 40.894 |
| Revenue per Share | 0.198 |
| Market Cap | 129,732,944 |
| Forward P/E | -1.99 |
| Beta | 2.36 |
| Previous Name | Frequency Therapeutics, Inc. |
| Website | https://www.korrobio.com |
As of Oct. 10, 2026, 9:19 a.m. EDT: Speculators are positioning defensively with heavy out-of-the-money put volume at deep strikes ($2.50, $5.00), suggesting a fear of significant downside or a 'catapult' scenario where the stock drops to zero. Conversely, call interest is concentrated near the money and slightly out-of-the-money, indicating a hope for a modest rebound to current levels rather than a massive rally. The implied volatility is elevated on deep puts, reflecting high uncertainty about the asset's survival.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.8284657 |
| Address1 | 60 First Street |
| Address2 | 2nd Floor Suite 250 |
| All Time High | 2,918.5 |
| All Time Low | 5.204 |
| Ask | 10.99 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 146,660 |
| Average Daily Volume3 Month | 147,460 |
| Average Volume | 147,460 |
| Average Volume10Days | 146,660 |
| Beta | 2.36 |
| Bid | 6.7 |
| Bid Size | 2 |
| Board Risk | 10 |
| Book Value | 7.019 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 8.81 |
| Current Ratio | 9.553 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 9.39 |
| Day Low | 8.55 |
| Debt To Equity | 40.894 |
| Display Name | Korro Bio |
| Dividend Yield | 0.0 |
| Earnings Timestamp | 1,786,019,400 |
| Earnings Timestamp End | 1,794,486,600 |
| Earnings Timestamp Start | 1,794,486,600 |
| Ebitda | -74,326,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.766 |
| Enterprise To Revenue | 23.892 |
| Enterprise Value | 56,909,940 |
| Eps Current Year | -5.234 |
| Eps Forward | -4.42125 |
| Eps Trailing Twelve Months | -9.88 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 11.8456 |
| Fifty Day Average Change | -3.0355997 |
| Fifty Day Average Change Percent | -0.2562639 |
| Fifty Two Week Change Percent | -82.84657 |
| Fifty Two Week High | 55.89 |
| Fifty Two Week High Change | -47.079998 |
| Fifty Two Week High Change Percent | -0.8423689 |
| Fifty Two Week Low | 5.204 |
| Fifty Two Week Low Change | 3.6060004 |
| Fifty Two Week Low Change Percent | 0.6929286 |
| Fifty Two Week Range | 5.204 - 55.89 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,570,109,400,000 |
| Float Shares | 10,512,197 |
| Forward Eps | -4.42125 |
| Forward P E | -1.9926493 |
| Free Cashflow | -41,390,124 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 57 |
| Fullday Change | -0.55999947 |
| Fullday Change Percent | -5.9765153 |
| Fullday Price | 8.81 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Gross Profits | -41,024,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00889 |
| Held Percent Institutions | 1.05232 |
| Implied Shares Outstanding | 14,725,646 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,699,228,800 |
| Last Split Factor | 1:50 |
| Long Business Summary | Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts. |
| Long Name | Korro Bio, Inc. |
| Market | us_market |
| Market Cap | 129,732,944 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_619256344 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-10-14 |
| Net Income To Common | -106,644,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 144,605,843 |
| Number Of Analyst Opinions | 10 |
| Open | 9.37 |
| Operating Cashflow | -67,948,000 |
| Operating Margins | -32.28338 |
| Overall Risk | 10 |
| Phone | 617 468 1999 |
| Prev Name | Frequency Therapeutics, Inc. |
| Previous Close | 9.37 |
| Price Eps Current Year | -1.683225 |
| Price Hint | 2 |
| Price To Book | 1.2551646 |
| Price To Sales Trailing12 Months | 54.46387 |
| Profit Margins | 0.0 |
| Quick Ratio | 9.11 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.36364 |
| Region | US |
| Regular Market Change | -0.559999 |
| Regular Market Change Percent | -5.97652 |
| Regular Market Day High | 9.39 |
| Regular Market Day Low | 8.55 |
| Regular Market Day Range | 8.55 - 9.39 |
| Regular Market Open | 9.37 |
| Regular Market Previous Close | 9.37 |
| Regular Market Price | 8.81 |
| Regular Market Time | 1,791,921,601 |
| Regular Market Volume | 263,652 |
| Return On Assets | -0.27953 |
| Return On Equity | -0.97691 |
| Revenue Per Share | 0.198 |
| Sand P52 Week Change | 0.17004645 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 14,725,646 |
| Shares Percent Shares Out | 0.113800004 |
| Shares Short | 1,675,219 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 1,483,705 |
| Short Name | Korro Bio, Inc. |
| Short Percent Of Float | 0.1274 |
| Short Ratio | 8.66 |
| Source Interval | 15 |
| State | MA |
| Symbol | KRRO |
| Target High Price | 30.0 |
| Target Low Price | 10.0 |
| Target Mean Price | 20.2 |
| Target Median Price | 21.5 |
| Total Cash | 115,036,000 |
| Total Cash Per Share | 7.812 |
| Total Debt | 42,213,000 |
| Total Revenue | 2,382,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -9.88 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 11.752325 |
| Two Hundred Day Average Change | -2.9423246 |
| Two Hundred Day Average Change Percent | -0.25036106 |
| Type Disp | Equity |
| Volume | 263,652 |
| Website | https://www.korrobio.com |
| Zip | 2,141 |